SAN FRANCISCO, July 22, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman is investigating claims in a pending class action alleging violations of U.S. securities laws by GRAIL, Inc. (NASDAQ: GRAL). The suit contends the company misled investors regarding the clinical design and efficacy of its landmark NHS-Galleri cancer screening trial.
Read more at prnewswire.comGRAL INVESTOR ALERT: GRAIL, Inc. (GRAL) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS
Barchart·07/22/2026 05:05:00
语音播报
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.